Last updated: 2026-09-16 12:18:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
BioXcel Therapeutics, Inc. (BTAI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0,07, with a market capitalisation of $2,31M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,07 to $4,29. This page covers its latest market performance, valuation, price trends and company information.
$2,31M | |
$0,09 | |
$1.144,00 | |
$0,07 | |
$0,12 | |
28,79M | |
6,19M | |
-- | |
$4,29 | |
$0,07 | |
-- | |
-- |
BioXcel Therapeutics, Inc. (BTAI) is trading at $0,09 in pre-market trading as of 2026-09-05 00:00:00, down 22,72% ($0,03) from the previous close of $0,12
Pre-market trading shows how investors are pricing BTAI before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, BioXcel Therapeutics, Inc. (BTAI) moved from $0,72 to $0,07, representing a decline of 89,73% ($0,65).
The stock traded between $0,07 and $0,76 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 47,34 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0,1%
BTAI is currently trading at $0,07, placing it 0,1% of the way from its 52-week low of $0,07 to its 52-week high of $4,29. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioXcel Therapeutics, Inc. (BTAI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.